JP2016088933A - Age production inhibitor and application thereof - Google Patents
Age production inhibitor and application thereof Download PDFInfo
- Publication number
- JP2016088933A JP2016088933A JP2015213529A JP2015213529A JP2016088933A JP 2016088933 A JP2016088933 A JP 2016088933A JP 2015213529 A JP2015213529 A JP 2015213529A JP 2015213529 A JP2015213529 A JP 2015213529A JP 2016088933 A JP2016088933 A JP 2016088933A
- Authority
- JP
- Japan
- Prior art keywords
- hair
- collagen
- composition
- improving
- production inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 93
- 239000003112 inhibitor Substances 0.000 title claims abstract description 48
- 102000008186 Collagen Human genes 0.000 claims abstract description 75
- 108010035532 Collagen Proteins 0.000 claims abstract description 75
- 229920001436 collagen Polymers 0.000 claims abstract description 73
- 210000004209 hair Anatomy 0.000 claims abstract description 70
- 239000000203 mixture Substances 0.000 claims abstract description 62
- 102000016942 Elastin Human genes 0.000 claims abstract description 36
- 108010014258 Elastin Proteins 0.000 claims abstract description 36
- 229920002549 elastin Polymers 0.000 claims abstract description 36
- 210000004761 scalp Anatomy 0.000 claims abstract description 33
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 22
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 21
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 20
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 20
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 20
- 230000003658 preventing hair loss Effects 0.000 claims abstract description 11
- 230000000694 effects Effects 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 23
- 244000062793 Sorghum vulgare Species 0.000 claims description 22
- 210000000720 eyelash Anatomy 0.000 claims description 22
- 235000019713 millet Nutrition 0.000 claims description 20
- 240000004371 Panax ginseng Species 0.000 claims description 14
- 235000008434 ginseng Nutrition 0.000 claims description 14
- 240000002234 Allium sativum Species 0.000 claims description 13
- 244000179886 Moringa oleifera Species 0.000 claims description 13
- 235000011347 Moringa oleifera Nutrition 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 13
- 235000004611 garlic Nutrition 0.000 claims description 13
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 12
- 240000000759 Lepidium meyenii Species 0.000 claims description 12
- 235000000421 Lepidium meyenii Nutrition 0.000 claims description 12
- 235000002789 Panax ginseng Nutrition 0.000 claims description 12
- 241000340987 Ptychopetalum olacoides Species 0.000 claims description 12
- 235000001978 Withania somnifera Nutrition 0.000 claims description 12
- 240000004482 Withania somnifera Species 0.000 claims description 12
- 235000003373 curcuma longa Nutrition 0.000 claims description 12
- 235000012902 lepidium meyenii Nutrition 0.000 claims description 12
- 229940109850 royal jelly Drugs 0.000 claims description 12
- 235000013976 turmeric Nutrition 0.000 claims description 12
- MUKYLHIZBOASDM-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid 2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound NC(=N)N(C)CC(O)=O.OCC(O)C(O)C(O)C(O)C(O)=O MUKYLHIZBOASDM-UHFFFAOYSA-N 0.000 claims description 11
- 239000009405 Ashwagandha Substances 0.000 claims description 11
- 241000219780 Pueraria Species 0.000 claims description 11
- 241000819233 Tribulus <sea snail> Species 0.000 claims description 11
- 239000012190 activator Substances 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 229940047183 tribulus Drugs 0.000 claims description 11
- DBRXOUCRJQVYJQ-CKNDUULBSA-N withaferin A Chemical compound C([C@@H]1[C@H]([C@@H]2[C@]3(CC[C@@H]4[C@@]5(C)C(=O)C=C[C@H](O)[C@@]65O[C@@H]6C[C@H]4[C@@H]3CC2)C)C)C(C)=C(CO)C(=O)O1 DBRXOUCRJQVYJQ-CKNDUULBSA-N 0.000 claims description 11
- 201000004384 Alopecia Diseases 0.000 claims description 10
- 230000003676 hair loss Effects 0.000 claims description 10
- 208000024963 hair loss Diseases 0.000 claims description 10
- 108010038807 Oligopeptides Proteins 0.000 claims description 5
- 102000015636 Oligopeptides Human genes 0.000 claims description 5
- 244000163122 Curcuma domestica Species 0.000 claims description 4
- 241000893536 Epimedium Species 0.000 claims description 2
- 235000018905 epimedium Nutrition 0.000 claims description 2
- 230000006872 improvement Effects 0.000 abstract description 26
- 238000009472 formulation Methods 0.000 abstract description 18
- 238000006243 chemical reaction Methods 0.000 abstract description 15
- 230000036252 glycation Effects 0.000 abstract description 12
- 239000004480 active ingredient Substances 0.000 abstract description 11
- 238000001727 in vivo Methods 0.000 abstract description 10
- 230000002265 prevention Effects 0.000 abstract description 5
- 239000000284 extract Substances 0.000 description 53
- 210000003491 skin Anatomy 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 230000006870 function Effects 0.000 description 20
- 238000012360 testing method Methods 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 241000196324 Embryophyta Species 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 240000003444 Paullinia cupana Species 0.000 description 10
- 235000000556 Paullinia cupana Nutrition 0.000 description 10
- 210000004204 blood vessel Anatomy 0.000 description 10
- 244000008991 Curcuma longa Species 0.000 description 8
- 230000032683 aging Effects 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000007423 decrease Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 210000004207 dermis Anatomy 0.000 description 6
- 230000006866 deterioration Effects 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 230000001256 tonic effect Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 235000013339 cereals Nutrition 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 210000000744 eyelid Anatomy 0.000 description 5
- 210000002752 melanocyte Anatomy 0.000 description 5
- 210000003899 penis Anatomy 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- 229940098465 tincture Drugs 0.000 description 5
- 208000007466 Male Infertility Diseases 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- 235000007195 Pennisetum typhoides Nutrition 0.000 description 4
- 239000003125 aqueous solvent Substances 0.000 description 4
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 4
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 4
- 235000001916 dieting Nutrition 0.000 description 4
- 230000037228 dieting effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000003779 hair growth Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 230000036299 sexual function Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 235000015961 tonic Nutrition 0.000 description 4
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 3
- 241000234282 Allium Species 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- 241000209504 Poaceae Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000008515 Setaria glauca Nutrition 0.000 description 3
- 244000273928 Zingiber officinale Species 0.000 description 3
- 235000006886 Zingiber officinale Nutrition 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000005225 erectile tissue Anatomy 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 235000008397 ginger Nutrition 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- 208000000509 infertility Diseases 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 231100000535 infertility Toxicity 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- -1 when it is young Polymers 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 240000007124 Brassica oleracea Species 0.000 description 2
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 2
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 2
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 2
- 235000002566 Capsicum Nutrition 0.000 description 2
- 241001672694 Citrus reticulata Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 244000236655 Diospyros kaki Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 208000007984 Female Infertility Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010021928 Infertility female Diseases 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- 244000241838 Lycium barbarum Species 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- 235000015468 Lycium chinense Nutrition 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 241000237502 Ostreidae Species 0.000 description 2
- 244000038248 Pennisetum spicatum Species 0.000 description 2
- 244000115721 Pennisetum typhoides Species 0.000 description 2
- 239000006002 Pepper Substances 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 235000016761 Piper aduncum Nutrition 0.000 description 2
- 240000003889 Piper guineense Species 0.000 description 2
- 235000017804 Piper guineense Nutrition 0.000 description 2
- 235000008184 Piper nigrum Nutrition 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 241001629703 Pueraria candollei var. mirifica Species 0.000 description 2
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- 229950004580 benzyl nicotinate Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 235000013477 citrulline Nutrition 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 235000005686 eating Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000020710 ginseng extract Nutrition 0.000 description 2
- 229940108690 glucosyl hesperidin Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 230000003752 improving hair Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229940059453 millet extract Drugs 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 235000020636 oyster Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 2
- 229940074410 trehalose Drugs 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 229930007845 β-thujaplicin Natural products 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000016704 Achillea millefolium ssp. borealis Nutrition 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 244000295724 Allium chinense Species 0.000 description 1
- 235000016790 Allium chinense Nutrition 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 241000209524 Araceae Species 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 241000370685 Arge Species 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000014161 Caesalpinia gilliesii Nutrition 0.000 description 1
- 244000003240 Caesalpinia gilliesii Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241000951471 Citrus junos Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000175448 Citrus madurensis Species 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 240000004270 Colocasia esculenta var. antiquorum Species 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 240000005109 Cryptomeria japonica Species 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- LKDRXBCSQODPBY-VRPWFDPXSA-N D-fructopyranose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-VRPWFDPXSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 235000002723 Dioscorea alata Nutrition 0.000 description 1
- 235000007056 Dioscorea composita Nutrition 0.000 description 1
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 description 1
- 235000005362 Dioscorea floribunda Nutrition 0.000 description 1
- 235000004868 Dioscorea macrostachya Nutrition 0.000 description 1
- 235000005361 Dioscorea nummularia Nutrition 0.000 description 1
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 235000008597 Diospyros kaki Nutrition 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241001016310 Epimedium grandiflorum Species 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 241000208688 Eucommia Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 235000017317 Fortunella Nutrition 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 239000006000 Garlic extract Substances 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241001316290 Gypsophila Species 0.000 description 1
- 241000208818 Helianthus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000013719 Houttuynia cordata Nutrition 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 241000546188 Hypericum Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 235000006350 Ipomoea batatas var. batatas Nutrition 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 241000758791 Juglandaceae Species 0.000 description 1
- 241000395050 Kaempferia parviflora Species 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 241000801118 Lepidium Species 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 241001336859 Lilium japonicum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 240000001463 Mertensia maritima Species 0.000 description 1
- 235000014272 Mertensia maritima var. asiatica Nutrition 0.000 description 1
- 235000003168 Mertensia maritima var. maritima Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 240000007695 Nandina domestica Species 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- 241000207836 Olea <angiosperm> Species 0.000 description 1
- 241000596467 Ononis Species 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 240000008114 Panicum miliaceum Species 0.000 description 1
- 235000007199 Panicum miliaceum Nutrition 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 244000062780 Petroselinum sativum Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONPXCLZMBSJLSP-CSMHCCOUSA-N Pro-Hyp Chemical compound C1[C@H](O)C[C@@H](C(O)=O)N1C(=O)[C@H]1NCCC1 ONPXCLZMBSJLSP-CSMHCCOUSA-N 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 244000018795 Prunus mume Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000109329 Rosa xanthina Species 0.000 description 1
- 241000545263 Salacia <hydroid> Species 0.000 description 1
- 244000151637 Sambucus canadensis Species 0.000 description 1
- 235000018735 Sambucus canadensis Nutrition 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 241001247145 Sebastes goodei Species 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 241001116498 Taxus baccata Species 0.000 description 1
- 241000907897 Tilia Species 0.000 description 1
- 241001521901 Tribulus lanuginosus Species 0.000 description 1
- 241000001727 Tropicoporus linteus Species 0.000 description 1
- 235000011453 Vigna umbellata Nutrition 0.000 description 1
- 240000001417 Vigna umbellata Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 244000195452 Wasabia japonica Species 0.000 description 1
- 235000000760 Wasabia japonica Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 235000007123 blue elder Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000011472 cat’s claw Nutrition 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 229940094517 chondroitin 4-sulfate Drugs 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 210000005226 corpus cavernosum Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 229940071120 dehydroacetate Drugs 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 235000007124 elderberry Nutrition 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000020706 garlic extract Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003648 hair appearance Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040511 liver extract Drugs 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000020733 paullinia cupana extract Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 229940112950 sage extract Drugs 0.000 description 1
- 235000020752 sage extract Nutrition 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000007949 saponins Chemical group 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037393 skin firmness Effects 0.000 description 1
- 230000008417 skin turnover Effects 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 239000008513 turmeric extract Substances 0.000 description 1
- 229940052016 turmeric extract Drugs 0.000 description 1
- 235000020240 turmeric extract Nutrition 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
Abstract
Description
本発明は、生体内タンパク質の糖化反応に着目したAGEs産生抑制剤およびその用途に関するものである。
さらに詳細には、単なる老化防止としての用途にとどまらず、改善が難しいED(勃起不全)、頭皮ダメージによる脱毛および白髪についてのケアや睫毛ケアに係る発明であり、その抗糖化剤としての適用形態も局所的なもののみならず、飲食形態を含めた全身的なケアとその方法を構成するものである。
The present invention relates to an AGEs production inhibitor that focuses on glycation reaction of in vivo proteins and uses thereof.
More specifically, it is an invention related to ED (erection dysfunction), hair loss due to scalp damage, and hair care and eyelash care, which is difficult to improve, not just as an anti-aging application, and its application form as an anti-glycation agent In addition to local things, they constitute systemic care and methods including food and drink forms.
「いつまでも若々しく過ごし続けたい」という私たち人類にとって永久の願いがある中、いわゆるアンチエイジングという「抗加齢医学」なるものが生まれ、老化プロセスとその原因克服のための医学体系が発展してきた。 While we have a permanent desire for mankind to “keep on being youthful forever”, what is called “anti-aging medicine”, so-called anti-aging, was born, and the medical system for overcoming the aging process and its causes has developed. It was.
最近では、老化のリスク因子として、糖化反応が注目されている。糖化反応は糖とタンパク質(アミノ酸類)が非酵素的に化学反応することを意味しており、当該化学反応により生成する物質の総称は、一般に、AGEs(アドバンスド・グリケーション・エンドプロダクツ)と呼ばれている。 Recently, a saccharification reaction has attracted attention as a risk factor for aging. The saccharification reaction means that sugar and protein (amino acids) chemically react non-enzymatically, and the generic name of substances generated by the chemical reaction is generally called AGEs (Advanced Glication End Products) It is.
健常人であっても、タンパク質のグリケーションは生じる。当該グリケーションは、紫外線や加齢により加速進行し、最終糖化反応生成物(以下、単に「AGEs」と呼ぶ)が産生し、蓄積する。昨今のライフスタイルや食生活の変化にともなう疾患も見逃せないリスク因子である。例えば、糖尿病を患った人は特にリスク高となり、AGEsが蓄積しやすく、これが原因となってさまざまな老化現象が加速される。 Even in healthy individuals, protein glycation occurs. The glycation is accelerated by ultraviolet rays or aging, and a final saccharification reaction product (hereinafter simply referred to as “AGEs”) is produced and accumulated. It is a risk factor that cannot be overlooked by diseases associated with recent lifestyle changes and dietary habits. For example, people with diabetes are particularly at high risk and AGEs are likely to accumulate, which accelerates various aging phenomena.
AGEsはタンパク質の硬化変性を伴うことから、その進行が生体組織の機能低下をもたらし、健康への種々の影響が懸念される。
しかも、タンパク質は脳、臓器、皮膚、頭皮、頭髪、爪、血中等の体内組織に存在することから、当然、AGEsの産生・蓄積の影響は全身に及ぶものである。
AGEs are accompanied by sclerosis and denaturation of proteins, and their progress brings about a decrease in the function of living tissues, and there are concerns about various effects on health.
Moreover, since proteins are present in body tissues such as the brain, organs, skin, scalp, scalp, nails, blood, etc., naturally, the effects of AGEs production / accumulation are systemic.
タンパク質の1種であるコラーゲンは、体重の約3割を占め、その4割が皮膚(目瞼皮膚を含む)、1乃至2割が骨や軟骨に存在する。その他、コラーゲンは血管、頭皮、臓器にも存在し、これら各部位で糖化反応は起こっている。 Collagen, which is a kind of protein, occupies about 30% of body weight, 40% of which is in the skin (including eyelid skin) and 10-20% is in bone and cartilage. In addition, collagen is also present in blood vessels, scalp, and organs, and saccharification occurs at each of these sites.
コラーゲンと同じく生体内で重要なタンパク質の1種であるエラスチンは、網目状に構成されたコラーゲンをつなぎ止めている弾力性をもたらす線維成分で、皮膚に弾力性を与える役割を担っている。 Elastin, which is one of the important proteins in the body like collagen, is a fiber component that brings elasticity to keep collagen in a mesh form, and plays a role in giving elasticity to the skin.
したがって、コラーゲンもエラスチンもAGEs産生の影響を直接的に受ける。このAGEs産生による影響を、特に皮膚、血管および頭皮において具体的にみると次のとおりである。 Therefore, both collagen and elastin are directly affected by AGE production. The effects of this AGE production are specifically as follows in the skin, blood vessels and scalp.
すなわち皮膚(目瞼皮膚を含む、以下、同義で用いることがある)では、コラーゲンタンパクやエラスチンファイバーなどのタンパク質の糖化がおこり、肌のハリを保持するコラーゲン線維の構造を破壊する生体反応が惹起される。コラーゲン合成を妨げる酵素(コラゲナーゼ)も活性化する。これにより、肌は正常の弾力性を失い、ハリやツヤのない状態に変色し、老廃物が皮膚の細胞に蓄積する。その結果、いわゆる黄ぐすみや黒ずみの原因を招き、肌の透明感が喪失する。
また、ダイエット中に肌荒れが起こるのは栄養バランスの欠如が影響していることが多いが、無理なダイエットを続けると、バリア機能を備えている角質層がダメージを受け保湿性が無くなるばかりか、糖化の影響で弾力性の低下が加速する。
瞼部位ではいわゆる目の隈が目立ち、睫毛(まつげ)は弾力性とハリ・ツヤが消失する。
That is, in the skin (including eyelid skin, which may be used synonymously hereinafter), glycation of proteins such as collagen protein and elastin fiber occurs, causing a biological reaction that destroys the structure of the collagen fibers that hold the skin firm. Is done. An enzyme that prevents collagen synthesis (collagenase) is also activated. As a result, the skin loses its normal elasticity, changes its color to a state free of firmness and gloss, and waste products accumulate in the skin cells. As a result, the cause of so-called yellowing and darkening is caused, and the transparency of the skin is lost.
In addition, it is often caused by lack of nutritional balance that causes rough skin during dieting, but if you continue unreasonable diet, the stratum corneum that has a barrier function will be damaged and moisture retention will be lost, Decrease in elasticity is accelerated by the effect of saccharification.
At the heel part, so-called eye lashes stand out, and the eyelashes lose their elasticity and elasticity.
血液中のAGEsは、血管の細胞に親和・接着性が高く、血管壁に蓄積しやすい。AGEsが血管壁に接着すると活性酸素が発生し、NO(一酸化窒素)を酸化する結果、血流が悪化する。疾患、例えば、EDとの関係では、勃起に必要な血液を運びにくくなる。特に糖尿病を罹患する場合に顕著に起こる現象でもある。ヒト陰茎は、解剖学的に3つの円柱部からなり、大部分がコラーゲンとエラスチンで構成されている。また、陰茎海綿体の勃起組織においては、コラーゲン線維とエラスチン繊維が血管・血液以外の重要な構成要素の一つであり、AGEsの産生は当該勃起組織にも悪影響を及ぼす。したがって、男性性機能の維持・回復には、AGEsの血管や陰茎海綿体の勃起組織における影響を防止することが極めて重要である。
近年深刻化している問題の一つに不妊治療がある。不妊治療は男性と女性それぞれ要因がことなることから、個別に治療の努力が払われているが、男性の場合は特にEDが要因であることが多く、その点からも抗糖化の着眼点は極めて意義がある。
一方、女性の場合は、糖化が直接の要因である。すなわち、糖化が卵子を劣化させ、その劣化の度合いが顕著になると排卵を不能にしてしまう。いずれにせよ、男性と女性の不妊治療としては、抗糖化という点が共通の鍵を握っていることになる。
AGEs in blood have high affinity and adhesion to blood vessel cells and are likely to accumulate in the blood vessel wall. When AGEs adhere to the blood vessel wall, active oxygen is generated, and as a result of oxidizing NO (nitrogen monoxide), blood flow deteriorates. In relation to diseases such as ED, it becomes difficult to carry blood necessary for erection. It is also a phenomenon that occurs particularly when suffering from diabetes. The human penis is anatomically composed of three cylindrical parts, most of which are composed of collagen and elastin. In the erectile tissue of the cavernous body of the penis, collagen fibers and elastin fibers are one of the important components other than blood vessels and blood, and the production of AGEs has an adverse effect on the erectile tissue. Therefore, to maintain and restore male sexual function, it is extremely important to prevent the influence of AGEs on the blood vessels and the erectile tissue of the corpus cavernosum.
One problem that has become more serious in recent years is infertility treatment. Infertility treatment has different factors for men and women, so efforts for treatment are being made individually, but in the case of men, ED is often a factor, and in that respect the point of anti-glycation is Very meaningful.
On the other hand, saccharification is a direct factor for women. That is, saccharification degrades the ovum, and ovulation becomes impossible when the degree of deterioration becomes significant. In any case, anti-glycation is a common key for male and female infertility treatment.
頭皮にも皮膚と同様に真皮層が存在する。頭皮の真皮層でAGEs架橋が生じるとか、髪の毛の主成分ケラチン(タンパク質の1つ)が糖化してAGEsがたまると、抜け毛や切れ毛、白髪が増える。
また、頭皮のハリは、真皮層に存在するエラスチン、ヒアルロン酸やコンドロイチン硫酸などが生み出している。
The scalp has a dermis layer as well as the skin. When AGEs cross-linkage occurs in the dermis layer of the scalp, or when AGEs accumulate due to glycation of the main component of hair, keratin (one of proteins), hair loss, cut hair, and gray hair increase.
In addition, the elasticity of the scalp is generated by elastin, hyaluronic acid, chondroitin sulfate, etc. present in the dermis layer.
毛髪への影響も大きく、この真皮層に存在するコラーゲンやエラスチンの糖化が進むと真皮層が硬化し、分泌腺や毛包、血管などに悪影響がもたらされる。その結果、毛髪をつくる活力が衰え、さらに髪のハリやツヤの消失という髪質への悪影響に及んでいく。髪の成長を司っているのは、毛根にある毛乳頭であるが、毛乳頭からの刺激を受けて毛母細胞は分裂、角化して髪となり、頭皮から伸長する。ここで、AGEsが毛根に蓄積すると、毛乳頭と毛母細胞の機能が制限される結果、十分に毛髪が成長できず抜け毛などが発生する。睫毛は、瞼の端部に生える体毛ととらえることができるが、毛髪同様に目瞼皮膚における糖化の影響によるコラーゲンやエラスチン等のタンパク質劣化が起こり、睫毛の弾力性やハリ・ツヤが消失し、再生サイクルも低下する。 The effect on hair is also great, and as the glycation of collagen and elastin present in the dermis layer progresses, the dermis layer hardens, causing adverse effects on secretory glands, hair follicles, blood vessels and the like. As a result, the vitality of making hair declines, and the hair quality is further affected by the loss of elasticity and gloss. The hair papilla located at the root of the hair roots controls the hair growth, but the hair matrix cells divide and keratinize into hair after receiving a stimulus from the hair papilla, and extend from the scalp. Here, when AGEs accumulate in the hair root, the functions of the hair papilla and hair matrix cells are limited. As a result, hair cannot grow sufficiently and hair loss occurs. Eyelashes can be regarded as body hair that grows at the ends of the eyelids, but as with hair, protein degradation such as collagen and elastin occurs due to the effect of glycation on the eyelid skin, and the elasticity and elasticity of the eyelashes disappear, The regeneration cycle is also reduced.
また、毛母細胞に隣接しメラノサイトがあり、毛母細胞は分裂時、当該メラノサイトからメラニン色素を取り込むことで黒や茶色の毛髪となるところ、メラノサイトにAGEsが蓄積するとメラニン色素を十分に供給できなくなり、白髪の原因にもなる。 In addition, there are melanocytes adjacent to the hair matrix cells, and when the hair matrix cells divide, they take in melanin pigment from the melanocytes and become black or brown hair. However, when AGEs accumulate in melanocytes, they can supply melanin sufficiently. It disappears and causes gray hair.
このように、頭皮、毛髪ならびに睫毛のケアという観点から見ても抗糖化(糖化対策)、すなわちAGEs産生抑制対策が注目されている。 Thus, from the viewpoint of scalp, hair and eyelash care, anti-glycation (saccharification measures), that is, AGEs production suppression measures are attracting attention.
コラーゲンについては、若いときはコラーゲン合成酵素の分泌が盛んであるため、コラーゲンが豊富に産生され、肌質や血管、頭皮の正常な状態が保持されるが、加齢とともにコラーゲン合成酵素は減少し、AGEs産生が進む。このようなステージがさらに進むと、もはや、いわゆるUV対策や保湿対策等の局所的なケアでは足りず、飲食等を含めた全身的なケアが必須となる。これはエラスチンに関しても同様である。 As for collagen, when it is young, collagen synthase is actively secreted, so abundant collagen is produced and the normal condition of skin quality, blood vessels, and scalp is maintained, but collagen synthase decreases with age. AGE production proceeds. If such a stage further progresses, local care such as so-called UV countermeasures and moisturizing countermeasures is no longer sufficient, and systemic care including eating and drinking becomes essential. The same applies to elastin.
コラーゲンの積極的な摂取や合成促進という観点からなされた従来技術は存在する。例えば、特許文献1には、コラーゲン蛋白,もしくはその加水分解物を大量摂取することにより、生体コラーゲンの生合成を促進させ、生体コラーゲンの新陳代謝の低下に伴う種々の疾病を改善できることが開示されている。特許文献2には、杜仲もしくはその抽出物と、人参もしくはその抽出物を必須成分とし、これにデオキシリボ核酸、コンドロイチン硫酸、コラーゲンもしくはその加水分解物及びハトムギエキスから選択配合することで皮膚のターンオーバー改善に効果を発揮する皮膚賦活剤が開示されている。特許文献3には、マコンブ仮根、アマチャ、高麗人参及びコラーゲンを配合した経口用育毛剤が毛母細胞の機能を促進し育毛効果を発揮し得ることが開示されている。特許文献4には、特定の植物を利用し、生体内のコラーゲン合成促進能を高めることで、生体組織の新陳代謝を活発にするコラーゲン合成促進剤組成物が開示されている。しかし、これらはいずれも本発明のような糖化反応に着目した抜本的対策ではなく、得られる効果としても十分ではない。 Conventional techniques existed from the viewpoint of active intake of collagen and promotion of synthesis. For example, Patent Document 1 discloses that by ingesting a large amount of collagen protein or a hydrolyzate thereof, biosynthesis of living collagen can be promoted and various diseases associated with a decrease in metabolism of living collagen can be improved. Yes. In Patent Document 2, Tochu or its extract and ginseng or its extract are essential components, and skin turnover by selectively selecting from deoxyribonucleic acid, chondroitin sulfate, collagen or its hydrolyzate and pearl extract. A skin activator that is effective for improvement is disclosed. Patent Document 3 discloses that an oral hair-restoring agent containing macombu temporary root, amateur, ginseng and collagen can promote the function of hair matrix cells and exhibit a hair-growing effect. Patent Document 4 discloses a collagen synthesis promoter composition that activates metabolism of living tissue by utilizing a specific plant and enhancing the ability to promote collagen synthesis in the living body. However, these are not drastic measures focusing on the saccharification reaction as in the present invention, and the obtained effects are not sufficient.
EDに関しては、その原因に不明な点が多い。ED改善のための治療剤においても問題点が多く、特に副作用が強く生命の危険におびやかされる薬剤も少なくない。副作用を軽減するための薬剤も開発されているが、依然として未解決の領域である。例えば、特許文献5乃至7が例示されるような薬剤投与によって一定の効果は認められるが、いまだ副作用の問題は残っており、日常生活で継続的に使用しづらい。また、これらは、本発明が目的とするAGEs産生抑制剤による改善に着目したものではない。 Regarding ED, there are many unclear points in its cause. There are also many problems with therapeutic agents for improving ED, and there are many drugs that have particularly strong side effects and are threatened to life. Drugs for reducing side effects have also been developed, but are still unresolved areas. For example, although certain effects are recognized by drug administration as exemplified in Patent Documents 5 to 7, the problem of side effects still remains, and it is difficult to use continuously in daily life. Moreover, these do not pay attention to the improvement by the AGEs production inhibitor which this invention aims at.
AGEs産生抑制剤の出願例としては、例えば、特許文献8乃至10が挙げられる。特許文献8および10は、医薬的な用途を開示している。また、特許文献9は、美容上の老化、とりわけ皮膚科学の側面から、主としてしわ、シミ、くすみおよびタルミ等の肌質改善の問題解決を開示している。しかしながら、これらはいずれも、抗糖化という観点からED改善、頭皮・頭髪に係る育毛剤へ適用するものではない。 Application examples of AGEs production inhibitors include, for example, Patent Documents 8 to 10. Patent documents 8 and 10 disclose pharmaceutical uses. Patent Document 9 discloses a solution for improving skin quality such as wrinkles, spots, dullness, and tarmi mainly from the viewpoint of cosmetic aging, especially dermatology. However, none of these are applied to ED improvement and a hair restorer for scalp and hair from the viewpoint of anti-glycation.
本発明の目的は、上記の問題点に鑑みて、コラーゲン、エラスチン等の生体内での糖化反応の結果、産生・蓄積するAGEsが引き起こす弊害のうち、特にED、頭皮・毛髪および睫毛のケアに係るAGEs産生抑制剤とその用途を提供することにある。 In view of the above-mentioned problems, the object of the present invention is, in particular, for the care of ED, scalp / hair and eyelashes among adverse effects caused by AGEs produced and accumulated as a result of in vivo saccharification reactions such as collagen and elastin. It is in providing the AGEs production inhibitor which concerns, and its use.
本発明者は、上記課題を解決するために鋭意検討した結果、生体内組織で必須のコラーゲン、エラスチン、ヒアルロン酸およびコンドロイチン硫酸を補給しつつ、生体内でのこれらタンパク質の糖化を防止すべく、AGEs産生抑制剤を併用した組成物を提供すること、あるいはその最適な使用方法を提供することによって、コラーゲン機能等の減退防止を図り、正常な男性性機能と頭皮・毛髪等機能を保持できることを見出し、本発明を完成した。 As a result of diligent studies to solve the above problems, the present inventor aims to prevent glycation of these proteins in vivo while supplementing essential collagen, elastin, hyaluronic acid and chondroitin sulfate in tissues in vivo. Providing a composition combined with an AGEs production inhibitor, or providing an optimal method for its use, to prevent decline in collagen function, etc., and to maintain normal male functions and functions such as scalp and hair The headline and the present invention were completed.
ED改善剤や頭皮・育毛等を含めた毛髪用製剤を開発するうえで重要な要素は、加齢による影響である。加齢によって、コラーゲンやエラスチンの生体内機能低下を防止するには、2つの側面から考える必要がある。外部からの量的な補充と生体内組織における内面ケアである。 An important factor in developing hair preparations including ED improving agents and scalp / hair growth is the effect of aging. In order to prevent deterioration of in vivo functions of collagen and elastin due to aging, it is necessary to consider from two aspects. Quantitative supplementation from the outside and internal care in in vivo tissues.
前者では、生体内で必須の成分を補うことであり、特に組織の弾力性に関わるコラーゲンとエラスチン、そしてこれらが介在することで保湿力が十分に発揮されるヒアルロン酸やコンドロイチン硫酸の補給が重要である。本発明では、コラーゲン又はコラーゲンペプチドを必須成分として、エラスチン、ヒアルロン酸及びコンドロイチン硫酸を組合せて補充成分とする。 In the former, it is necessary to supplement essential components in the body. Especially, it is important to supplement collagen and elastin which are related to tissue elasticity, and hyaluronic acid and chondroitin sulfate, which can sufficiently exert moisture retention. It is. In the present invention, collagen or collagen peptide is an essential component, and elastin, hyaluronic acid and chondroitin sulfate are combined as a supplement component.
後者では、生体内に存在するタンパク質のち、コラーゲンおよびエラスチンの減少、特に糖化反応による影響を防止するために、AGEs産生を抑制することである。ここで、AGEs産生抑制剤としては、ED改善、頭皮ケア(毛髪機能改善・脱毛および白髪予防)及び睫毛ケアという用途に鑑みて、血流、滋養強壮効果を有する素材の中からAGEs産生抑制効果のあるものを種々スクリーニング後、好適なものとして見出し、本発明に供することとした。すなわち、アシュワガンダ、イカリソウ、オタネニンジン、ガラナ、黒ウコン、トリビュラス、トンカットアリ、ニンニク、プエラリア、マカ、ムイラプアマ、モリンガ、メシマコブ及びローヤルゼリーから選ばれた1種以上を有効成分として併用するに至った。これらは、いずれも新規のAGEs産生抑制剤である。 The latter is to suppress the production of AGEs in order to prevent the decrease of collagen and elastin after the proteins present in the living body, particularly the influence of saccharification reaction. Here, as an AGEs production inhibitor, in view of uses such as ED improvement, scalp care (hair function improvement / hair loss and white hair prevention) and eyelash care, AGEs production inhibitory effect from among materials having blood flow and nourishing tonic effect After being screened variously, it was found as suitable and used for the present invention. That is, one or more selected from Ashwagandha, Epimedium, Panax ginseng, Guarana, Black Turmeric, Tribulus, Tonkat Ali, Garlic, Pueraria, Maca, Muirapuama, Moringa, Meshimakobu and Royal Jelly have been used as active ingredients. These are all novel AGEs production inhibitors.
さらに追試する過程において、これらのAGEs産生抑制効果を賦活する素材として、ミレットを見出し、本発明を完成するに至った。 Furthermore, in the process of further testing, millet was found as a material for activating these AGEs production inhibitory effects, and the present invention was completed.
すなわち、本発明によれば、以下の(1)乃至(14)に記載のAGEs産生抑制剤およびその用途が提供される。 That is, according to this invention, the AGEs production inhibitor as described in the following (1) thru | or (14) and its use are provided.
(1)アシュワガンダ、イカリソウ、オタネニンジン、ガラナ、黒ウコン、トリビュラス、トンカットアリ、ニンニク、プエラリア、マカ、ムイラプアマ、モリンガ、メシマコブおよびローヤルゼリーから選ばれた1種以上を有効成分とするAGEs産生抑制剤。
(2)AGEs産生抑制効果賦活剤としてミレットを添加したことを特徴とする(1)に記載のAGEs産生抑制剤。
(3)コラーゲンおよび/又はコラーゲンペプチドを主成分とし、これにエラスチン、ヒアルロン酸およびコンドロイチン硫酸から選ばれる少なくとも1種で構成される組成物に、(1)または(2)に記載のAGEs産生抑制剤を添加してなることを特徴とするED改善用組成物。
(4)コラーゲンおよび/又はコラーゲンペプチドを主成分とし、これにエラスチン、ヒアルロン酸およびコンドロイチン硫酸から選ばれる少なくとも1種で構成される組成物に、(1)または(2)に記載のAGEs産生抑制剤を添加してなることを特徴とする毛髪・睫毛用組成物。
(5)コラーゲンペプチドがオリゴペプチドであることを特徴とする(3)および(4)に記載のED改善用または毛髪・睫毛用組成物。
(6)適用が飲食形態であることを特徴とする(3)乃至(5)に記載のED改善用又は毛髪・睫毛用組成物。
(7)適用が非経口の外用形態であることを特徴とする(4)または(5)に記載の毛髪・睫毛用組成物。
(8)コラーゲンおよび/又はコラーゲンペプチドを主成分とし、これにエラスチン、ヒアルロン酸およびコンドロイチン硫酸から選ばれる少なくとも1種で構成される組成物において、AGEs産生抑制剤を添加し、当該組成物の適用によってEDを改善する方法。
(9)AGEs産生抑制剤が、アシュワガンダ、イカリソウ、オタネニンジン、ガラナ、黒ウコン、トリビュラス、トンカットアリ、ニンニク、プエラリア、マカ、ムイラプアマ、モリンガ、メシマコブおよびローヤルゼリーから選ばれた1種以上であり、さらにAGEs産生抑制効果賦活剤としてミレットを添加したことを特徴とする(8)に記載のED改善化方法。
(10)コラーゲンおよび/又はコラーゲンペプチドを主成分とし、これにエラスチン、ヒアルロン酸およびコンドロイチン硫酸から選ばれる少なくとも1種で構成される組成物において、AGEs産生抑制剤を添加し、当該組成物を適用することによって、頭皮機能を改善し、脱毛および白髪を防止する方法。
(11)AGEs産生抑制剤が、アシュワガンダ、イカリソウ、オタネニンジン、ガラナ、黒ウコン、トリビュラス、トンカットアリ、ニンニク、プエラリア、マカ、ムイラプアマ、モリンガ、メシマコブおよびローヤルゼリーから選ばれた1種以上であり、さらにAGEs産生抑制効果賦活剤としてミレットを添加したことを特徴とする(10)に記載の頭皮改善による脱毛および白髪の防止方法。
(12)コラーゲンペプチドがオリゴペプチドであることを特徴とする(8)乃至(11)に記載のED改善化方法または頭皮改善による脱毛および白髪の防止方法。
(13)適用が飲食形態であることを特徴とする(8)及び(9)に記載のED改善化の方法。
(14)適用が非経口の外用形態であることを特徴とする(10)及び(11)に記載の頭皮改善による脱毛および白髪の防止方法。
(1) An AGEs production inhibitor comprising as an active ingredient at least one selected from Ashwagandha, Ikarisou, Panax ginseng, Garana, Black turmeric, Tribulus, Tonkat Ali, Garlic, Pueraria, Maca, Muirapuama, Moringa, Meshimakobu, and Royal Jelly.
(2) The AGEs production inhibitor according to (1), wherein millet is added as an activator for inhibiting AGEs production.
(3) A composition comprising at least one selected from elastin, hyaluronic acid and chondroitin sulfate, comprising collagen and / or collagen peptide as a main component, and inhibiting AGEs production according to (1) or (2) A composition for improving ED, comprising adding an agent.
(4) A composition comprising at least one selected from elastin, hyaluronic acid, and chondroitin sulfate, comprising collagen and / or collagen peptide as a main component, and inhibiting AGEs production according to (1) or (2) A composition for hair and eyelashes comprising an agent added.
(5) The composition for improving ED or for hair and eyelashes according to (3) and (4), wherein the collagen peptide is an oligopeptide.
(6) The composition for improving ED or for hair and eyelashes according to (3) to (5), wherein the application is in the form of food and drink.
(7) The composition for hair and eyelashes according to (4) or (5), wherein the application is a parenteral external form.
(8) In a composition comprising collagen and / or collagen peptide as a main component and at least one selected from elastin, hyaluronic acid and chondroitin sulfate, an AGEs production inhibitor is added, and the composition is applied To improve the ED.
(9) The AGEs production inhibitor is at least one selected from Ashwagandha, Ikariso, Panax ginseng, guarana, black turmeric, tribulus, tongkat ali, garlic, Pueraria, maca, muirapuama, moringa, mesimacob, and royal jelly. The method for improving ED according to (8), wherein millet is added as an activator for suppressing AGEs production.
(10) A composition comprising at least one selected from elastin, hyaluronic acid and chondroitin sulfate as a main component of collagen and / or collagen peptide, to which an AGEs production inhibitor is added, and the composition is applied To improve scalp function and prevent hair loss and gray hair.
(11) The AGEs production inhibitor is at least one selected from Ashwagandha, Ikariso, Panax ginseng, guarana, black turmeric, tribulus, tongkat ali, garlic, Pueraria, maca, muirapuama, moringa, mesimacob, and royal jelly. The method for preventing hair loss and gray hair by improving the scalp according to (10), wherein millet is added as an activator for suppressing AGEs production.
(12) The method for improving ED or the method for preventing hair loss and white hair by improving the scalp according to (8) to (11), wherein the collagen peptide is an oligopeptide.
(13) The method for improving ED according to (8) and (9), wherein the application is a food and drink form.
(14) The method for preventing hair loss and gray hair by improving the scalp according to (10) and (11), wherein the application is a parenteral external form.
本発明によれば、特定のAGEs産生抑制剤を外用及び/又は経口の形態で最適に適用することで、皮膚組織におけるコラーゲンおよびエラスチン量の減少が防止でき、機能改善・正常化が図られる。その結果、ダイエット中の肌の保湿、肌・陰茎のハリおよびツヤが保持でき、女性の排卵機能正常化作用および男性性機能、特にED改善を図ることができる。さらに当該ED改善により、男性の不妊症治療としての波及効果も得ることができる。
頭皮においては、毛母細胞と隣接するメラノサイトの機能正常化が図られ、毛髪の活性(ハリとツヤの改善)ならびに脱毛と白髪の防止が図られる。目瞼皮膚においては、睫毛の弾力性やハリ・ツヤが保持でき、いわゆるエクステによるダメージ防止も図ることができる。さらに本発明によれば、これらの効果はAGEs産生抑制の賦活剤、特にミレットの添加によって増強し得るものである。ミレット自体には育毛効果があるため、頭皮機能改善用の素材として用いる場合には、AGEs産生抑制の賦活効果のみならず、育毛の有効成分としてのデュアル効果が発揮され得るものである。
According to the present invention, by applying a specific AGEs production inhibitor optimally in an external and / or oral form, a decrease in the amount of collagen and elastin in the skin tissue can be prevented, and functional improvement and normalization can be achieved. As a result, it is possible to keep the skin moisturized and the skin and penis firmness and luster in the diet, and to normalize the female ovulation function and male sex function, particularly ED. Furthermore, the ED improvement can also have a ripple effect as a treatment for male infertility.
In the scalp, the function of the melanocytes adjacent to the hair matrix cells is normalized, and the hair activity (improves firmness and gloss) as well as the prevention of hair loss and white hair. The eyelid skin can retain the elasticity and elasticity of eyelashes, and can prevent damage caused by so-called extensions. Furthermore, according to the present invention, these effects can be enhanced by the addition of an activator of AGEs production suppression, particularly millet. Since millet itself has a hair growth effect, when used as a material for improving scalp function, not only the activation effect of inhibiting AGEs production but also the dual effect as an active ingredient for hair growth can be exhibited.
以下、本発明を実施するための具体的な形態について詳細に説明するが、本発明の技術的範囲は以下に開示する具体的な形態のみに限定されるものではない。 Hereinafter, specific modes for carrying out the present invention will be described in detail. However, the technical scope of the present invention is not limited to the specific modes disclosed below.
本発明における第1の発明は、加齢による皮膚老化防止用やダイエット中における肌荒れ改善作用のみならず、毛髪等の改善及びED改善用を意図して見出した特定のAGEs産生抑制剤である。すなわち、女性の不妊症治療、睫毛、頭皮ケア(毛髪機能改善・脱毛および白髪予防)ならびにED改善という用途(当該用途に関連する男性の不妊症治療を含む用途)に鑑みて、血流、滋養強壮効果を有する素材の中からAGEs産生抑制効果のあるものをスクリーニングしたところ、アシュワガンダ、イカリソウ、オタネニンジン、ガラナ、黒ウコン、トリビュラス、トンカットアリ、ニンニク、プエラリア、マカ、ムイラプアマ、モリンガ、メシマコブおよびローヤルゼリーが好適な素材として見出された。 The first invention in the present invention is a specific AGEs production inhibitor found not only for preventing skin aging due to aging and for improving rough skin during dieting but also for improving hair and the like and for improving ED. In other words, blood flow, nourishment in view of the use of female infertility treatment, eyelashes, scalp care (hair function improvement / hair loss and white hair prevention) and ED improvement (use including male infertility treatment related to the use) After screening for materials that have an AGEs-inhibiting effect from materials with a tonic effect, Ashwagandha, Ikarisou, Panax ginseng, Guarana, Black turmeric, Tribulus, Tonkat Ali, Garlic, Pueraria, Maca, Muirapuama, Moringa, Meshimakob and Royal Jelly Was found as a suitable material.
ここで、アシュワガンダとは、学名を「Withania somnifer」といい、インドに自生するナス科の常緑低木である。インドでは、古くからアーユルヴェーダとして利用されている。 Here, Ashwagandha is the scientific name “Withania somnifer” and is an evergreen shrub of the solanaceous family that grows naturally in India. In India, it has long been used as Ayurveda.
イカリソウ(碇草、錨草 Epimedium grandiflorum var. thunbergianum)はメギ科イカリソウ属の落葉多年草であり、全草は淫羊霍(いんようかく)という生薬として有名である。 Epimedium grandiflorum var. Thunbergianum is a deciduous perennial plant belonging to the genus Eucalyptus, and the whole plant is famous as a herbal medicine called oleam.
オタネニンジン(Panax ginseng C. A. Meyer)とは、ウコギ科の多年草であり、主要な薬用部位は根で有用成分はジンセノサイドとよばれるサポニン群であり、古くから服用されてきた。 Panax ginseng C. A. Meyer is a perennial plant belonging to the family Araceae, whose main medicinal site is the root and the useful ingredient is a saponin group called ginsenoside, which has been taken for a long time.
ガラナ (Paullinia cupana) は、ムクロジ科ガラナ属のつる植物であり、原産地はアマゾン川流域である。実は小さく丸く、房状に生る。果皮は赤く、熟すると実が弾け、黒い種が現れる。ガラナの種子にはカフェインやタンニンが豊富に含まれている。 Guarana (Paullinia cupana) is a vine plant belonging to the genus Guarana, which is from the Amazon River basin. Actually, it is small and round, and grows like a tuft. The skin is red, and when ripe, the fruit flips and black seeds appear. Guarana seeds are rich in caffeine and tannins.
黒ウコン(Kaempferia parviflora)は、別名を「クラチャイダム」、「黒ショウガ」ともいい、熱帯地方で栽培するショウガ科ケンペリア属の植物である。日本では唯一沖縄だけで栽培されている。 Black turmeric (Kaempferia parviflora), also known as “Kurachaidum” or “Black Ginger”, is a plant belonging to the genus Kempelia in the tropical region. In Japan, it is cultivated only in Okinawa.
トリビュラス(Tribulus Terrestris)は、南アジアから東欧にかけて自生するハマビシ科の多年草である。 Tribulus Terrestris is a terrestrial perennial that grows naturally from South Asia to Eastern Europe.
トンカットアリは、マレーシア、インドシナやスマトラ等の熱帯雨林に見られるニガキ科の潅木の1種で、成長すると高さ10メートルに達します。 Tonkat Ali is a species of oyster family shrub found in tropical rainforests such as Malaysia, Indochina and Sumatra, and reaches 10 meters in height when grown.
ニンニク(Allium sativum)はネギ属の多年草で、球根(鱗茎)を香辛料として用いる。 Garlic (Allium sativum) is a perennial plant belonging to the genus Allium and uses bulbs as bulbs.
プエラリア(学名:Pueraria mirifica)は、ミャンマーの山岳地帯など、亜熱帯地域の落葉樹林に自生するマメ科クズ属の植物である。 Pueraria mirifica (Scientific name: Pueraria mirifica) is a plant belonging to the genus Leguminosae that grows naturally in deciduous forests in subtropical regions such as the mountainous areas of Myanmar.
マカ(属名 Lepidium)は、南米ペルーに植生するアブラナ科の多年生植物である。 Maca (genus name Lepidium) is a cruciferous perennial plant that grows in Peru, South America.
ムイラプアマ(Ptychopetalum olacoides;ボロボロノキ科)は、アマゾンに生息しているハーブの一種である。 Muirapuama (Ptychopetalum olacoides) is a kind of herb that lives in the Amazon.
モリンガ(学名:Moringa oleifera Lam.)は、和名でワサビノキとも呼ばれ、亜熱帯・熱帯地方に自生する。特に北インドやフィリピンで多くみられる。 Moringa (scientific name: Moringa oleifera Lam.) Is a Japanese name, also called wasabi tree, and grows naturally in the subtropical and tropical regions. This is particularly common in North India and the Philippines.
メシマコブ(Phellinus linteus)は、日本原産の薬用キノコである。
長崎県の男女群島にある「女島(メシマ)」に野生の「桑」の幹に寄生する「コブ」状のキノコである事から、その名がついたとされ、学術的には担子菌類のタバコウロコタケ科キコブタケ属に属する。
Meshimakobu (Phellinus linteus) is a medicinal mushroom native to Japan.
“Meshima” in the gender archipelago of Nagasaki Prefecture is named “mump” -shaped mushrooms that parasitize the trunk of wild “mulberry”. It belongs to the genus Mushroom.
ローヤルゼリー(royal jelly) は、ミツバチが 花粉や蜂蜜を食べ、体内で分解・合成し、分泌する 物質である。 Royal jelly is a substance that bees eat pollen and honey, break down, synthesize, and secrete.
これら本発明に係るAGEs産生抑制剤は、粉末等にして素材そのものを用いても良いが、その活性を効率的に発揮させるためには各素材について、水性溶媒で抽出したエキスを用いるのが好ましい。水性溶媒としては、水及び/又は低級アルコール抽出したエキスを用いることができ、低級アルコールとしては、エタノールが好適である。 These AGEs production inhibitors according to the present invention may be used as raw materials as powders or the like, but it is preferable to use an extract extracted with an aqueous solvent for each material in order to exhibit its activity efficiently. . As the aqueous solvent, water and / or an extract extracted with a lower alcohol can be used, and ethanol is preferable as the lower alcohol.
本発明では、これら特定のAGEs産生抑制剤から選ばれた1種以上に、AGEs産生抑制効果を増強するために、ミレットを使用することがきる。 In this invention, millet can be used in order to enhance the AGEs production inhibitory effect to 1 or more types chosen from these specific AGEs production inhibitors.
ここでミレット(millet)とは、雑穀を意味し、主穀ではない穀類の総称である。雑穀は、狭義ではイネ科の草本のキビ亜科に含まれる穀類を指すが、広義には、キビ亜科以外のイネ科穀物では、モロコシ属のソルガム、ハトムギも含まれ、大豆や小豆の豆類等を含む。本発明では、これらのうち特にイネ科の一年草であるキビ(Panicum miliaceum)およびトウジンビエ(Pennisetum glaucum)である。トウジンビエは、イネ科チカラシバ属に属する単子葉草本で、英名はパールミレット(Pearl millet.)と呼ばれる。また、クロキビの別称がある。 Here, millet means millet and is a general term for cereals that are not main grains. Minor grains refer to cereals included in the herbaceous family of millet in the narrow sense, but in the broader sense, cereals other than millet include sorghum and pearl barley in the genus Sorghum, and beans of soybeans and red beans. Etc. In the present invention, among these, especially the annual grasses of the family Gramineae (Panicum miliaceum) and pearl millet (Pennisetum glaucum). The pearl millet is a monocotyledonous herb belonging to the genus Chileashiba, and its English name is called Pearl millet. There is another name for black millet.
本発明のミレットは、AGEs産生抑制剤と同様、種子等を粉末等にして素材そのものを用いても良いが、その活性を効率的に発揮させるために水性溶媒で抽出したエキスを用いるのが好ましい。水性溶媒としては、水及び/又は低級アルコール抽出したエキスを用いることができ、低級アルコールとしては、エタノールが好適である。 The millet of the present invention may use the raw material itself by making seeds into powder etc., as with the AGEs production inhibitor, but it is preferable to use an extract extracted with an aqueous solvent in order to efficiently exhibit its activity. . As the aqueous solvent, water and / or an extract extracted with a lower alcohol can be used, and ethanol is preferable as the lower alcohol.
ミレットエキスはヨーロッパの中世から飲む育毛剤として知られているが、本発明のようにAGEs産生抑制剤の賦活剤としての用途は知られていない。 Millet extract is known as a hair restorer that has been drunk from the Middle Ages of Europe, but its use as an activator of AGEs production inhibitor as in the present invention is not known.
本発明では、上記特定のAGEs産生抑制剤から選ばれた1種以上またはこれらにミレットを添加した組成物をそのまま使用できるが、外用剤又は飲食の形態として適用するための有効成分(機能性成分)としても使用することができる。 In the present invention, one or more selected from the above-mentioned specific AGEs production inhibitors or a composition obtained by adding millet to these can be used as they are, but an active ingredient (functional ingredient) for application as an external preparation or a form of food and drink ) Can also be used.
外用での適用に際して、公知の経皮吸収促進剤の併用は任意であり、使用部位に応じて製剤設計する。これらの適用により、表皮や真皮におけるコラーゲン等のタンパク質の糖化反応を抑制し、皮膚のハリや皺改善ならびにダイエット中における肌荒れ予防に有用な効果を発揮することができる。また、頭皮に適用することで、当該頭皮におけるAGEsの産生蓄積を抑制することができ、毛母細胞が活性化する。またメラノサイトの機能が正常化する。その結果、それぞれ、脱毛が防止でき、白髪も防止できる。さらに、陰茎では、吸収されたAGEs産生抑制剤によって血管壁へのAGEsの接着・蓄積が抑制できるため、活性酸素による一酸化窒素の酸化が抑制でき、血流が改善する。そのうえ、本発明の素材が本来有する滋養強壮や血流促進機能の働きが相俟って、陰茎海綿体での血流改善はさらに促進され、勃起力が改善する。なお、陰茎部の組織は薬剤等の浸透・吸収性が良いため、外用剤塗布でも十分な効果が期待できるが、飲食等の経口を併用するとなお期待が見込める。特に女性の不妊治療を企図した場合、飲食によって体内に抗糖化剤をデリバリーすることで、血中の有効濃度を維持できることから、経口摂取は糖化による卵の劣化を強力に抑制し得るために最適方法である。 When applied externally, the combination use of a known percutaneous absorption enhancer is optional, and the formulation is designed according to the site of use. By applying these, the glycation reaction of proteins such as collagen in the epidermis and dermis can be suppressed, and the effects useful for improving skin firmness and wrinkles and preventing rough skin during dieting can be exhibited. Moreover, by applying to the scalp, production and accumulation of AGEs in the scalp can be suppressed, and hair matrix cells are activated. Moreover, the function of melanocytes is normalized. As a result, hair loss can be prevented and white hair can also be prevented. Furthermore, in the penis, the absorbed / aged AGEs production inhibitor can suppress the adhesion / accumulation of AGEs to the blood vessel wall, so that the oxidation of nitric oxide by active oxygen can be suppressed and the blood flow can be improved. In addition, the nutritional tonic and blood flow promoting function inherent in the material of the present invention are combined, and blood flow improvement in the penile cavernous body is further promoted and erection power is improved. In addition, since the tissue of the penis part has good penetrability and absorbability of drugs and the like, a sufficient effect can be expected even by applying an external preparation, but expectation is still expected when combined with oral use such as food and drink. Especially when intended for the treatment of infertility in women, the effective concentration in the blood can be maintained by delivering an anti-glycation agent into the body by eating and drinking, so oral intake is optimal because it can strongly suppress egg degradation due to saccharification Is the method.
本発明の外用剤は、医薬品、医薬部外品および化粧品のカテゴリーとして許容しうる形態を含むものであり、その剤型としては、本発明の目的を損なわない範囲であれば特に制約されない。例えば、クリーム、軟膏、乳剤、リニメント剤、ペースト剤、ローション、乳液、エッセンス、ゲル剤、シャンプー、リンス、コンディショナー及びトニックなどの公知の形態があげられる。 The external preparation of the present invention includes forms acceptable as pharmaceuticals, quasi drugs, and cosmetics, and the dosage form is not particularly limited as long as it does not impair the object of the present invention. Examples thereof include known forms such as creams, ointments, emulsions, liniments, pastes, lotions, emulsions, essences, gels, shampoos, rinses, conditioners and tonics.
製剤設計時の配合基剤(賦形剤)については、皮膚施用上許容し得る任意の液状及び固形状の原料を幅広く使用できる。その際、必要に応じて保湿剤、防腐剤、酸化防止剤など種々の汎用の添加剤を加えることができる。 As the formulation base (excipient) at the time of formulation design, any liquid and solid raw materials acceptable for skin application can be used widely. At that time, various general-purpose additives such as a humectant, a preservative, and an antioxidant can be added as necessary.
保湿剤としては、例えば、尿素、グリセリン、プロピレングリコール、1,3−ブチレングリコール、ソルビトール、マンニトール、ポリエチレングリコール、ジプロピレングリコール等の多価アルコール類、セラミド類、ヘパリン類似様物質、グルコサミン、フコイダン、トリメチルグリシン、べタイン、海藻エキス(アルゲコロイド)等を例示することができる。当該保湿剤の併用は、特にダイエット中に起こり得る肌荒れ改善を企図した場合の処方設計として有用な選択である。 Examples of humectants include urea, glycerin, propylene glycol, 1,3-butylene glycol, sorbitol, mannitol, polyethylene glycol, dipropylene glycol and other polyhydric alcohols, ceramides, heparin-like substances, glucosamine, fucoidan, Examples include trimethylglycine, betaine, seaweed extract (Arge colloid) and the like. The combined use of the moisturizing agent is a useful choice as a prescription design particularly when intended to improve rough skin that may occur during dieting.
防腐剤としては、例えば、安息香酸塩、ソルビン酸塩、デヒドロ酢酸塩、パラオキシ安息香酸エステル、塩化ベンザルコニウム、ヒノキチオール、レゾルシン、エタノール、フェノキシエタノール等を例示することができる。 Examples of the preservative include benzoate, sorbate, dehydroacetate, p-hydroxybenzoate, benzalkonium chloride, hinokitiol, resorcin, ethanol, phenoxyethanol, and the like.
酸化防止剤としては、例えば、ジブチルヒドロキシトルエン、ブチルヒドロキシアニソール、没食子酸プロピル、アスコルビン酸等を例示することができる。 Examples of the antioxidant include dibutylhydroxytoluene, butylhydroxyanisole, propyl gallate, ascorbic acid and the like.
本発明の有効成分のほか、外用剤に通常用いられる他の機能性成分は、本発明の効果や目的を損なわない範囲で任意に配合可能である。具体的には、例えば、塩化リゾチーム、グリチルリチン酸又はその塩、アラントインなどの消炎剤、ベータグルカン等の免疫賦活剤、男性ホルモン(メチルテストステロン)、グルコシルヘスペリジン、シトルリン、ビタミンEニコチネート、ニコチン酸、ニコチン酸アミド、ニコチン酸ベンジル、ショウキョウチンキ、センブリエキス、トウガラシチンキなどの末梢血管拡張剤、ヒノキチオール、塩化ベンザルコニウム、ウンデシレン酸などの抗菌剤、プラセンタ抽出液、肝臓抽出物、牡蠣抽出液、アルテア抽出液、オノニス抽出液、カワラヨモギ抽出液、キダチアロエ抽出液、紅参抽出液、鹿角霊芝抽出液、芭蕉(バナナ果皮)抽出液、ゲンノショウコ抽出液、フキ根抽出液、ササユリ抽出液、西洋ノコギリソウ抽出液、西洋南瓜(乾燥種子)抽出液、セージ抽出液、セロリ抽出液、ダイズ抽出液、タチジャコウ抽出液、チンピ抽出液、ヒキオコシ抽出液、フキタンポポ抽出液、ボタン抽出液、マコンブ抽出液、メリッサ抽出液、ユズ抽出液、レスベラトロール、乳酸菌培養抽出物などの動物・植物・微生物由来の各種抽出物、および野菜・果物・野草を発酵させたエキス(以下、野草発酵エキス)などが挙げられる。当該野草発酵エキスの原料としては、例えば、ヨモギ、ドクダミ、キダチアロエ、ウコン、高麗ニンジン、クコの実、ハト麦、オトギリ草、クマザサ、レイシ、タンポポの根、レイセンソウ、モモの葉、イチョウ葉、エジスグサノ種子、ニンドウ、イチジクの葉、ハブ草、ベニバナ、エゾウコギ、アマチャヅル、ラカンカ、トチュウ葉、エンメイ草、ビワ葉、モロヘイヤ、クコ葉、セツコツボク、アカメガシワ、オオバコ、トゥルシー、カンゾウ、マツ葉、ナンテンの葉、スギナ、アマドコロ、ツユクサ、メグスリの木、ツルナ、やまいも、カキの葉、カミツレ、カリン、シソの葉、ミカンの皮、ショウガ、クワ葉、センシンレン、キンカン、タマネギ外皮、田七人参、キキョウ根、ナツメ、サラシア、トウガラシ、イチイの実、紅参、ルイボス、アムラの実、ツボクサ、ハッショウマメ、ムイラブアマ、イボナシツヅラフジ、キャッツクロー、コンブ、フノリ、ミカン、リンゴ、パイナップル、ブドウ、イチジク、ウメ、メロン、グレープフルーツ、レモン、アンズ、ニンジン、タマネギ、パセリ、ゴボウ、ニンニク、ラッキョウ、キャベツ、シイタケなどを用途に応じて適宜選択し使用することができる。 In addition to the active ingredient of the present invention, other functional ingredients usually used in external preparations can be arbitrarily blended within a range not impairing the effects and purposes of the present invention. Specifically, for example, lysozyme chloride, glycyrrhizic acid or salts thereof, anti-inflammatory agents such as allantoin, immunostimulants such as beta-glucan, male hormone (methyltestosterone), glucosyl hesperidin, citrulline, vitamin E nicotinate, nicotinic acid, nicotine Peripheral vasodilators such as acid amide, benzyl nicotinate, ginger tincture, assembly extract, pepper tincture, antibacterial agents such as hinokitiol, benzalkonium chloride, undecylenic acid, placenta extract, liver extract, oyster extract, Artea Extract, Ononis extract, Kawaramugi extract, Kidachi aloe extract, Red ginseng extract, Deer horned turf extract, Persimmon (banana peel) extract, Ginseng extract, Japanese persimmon root extract, Sasayuri extract, Western yarrow extract Liquid, western nanban (dry seeds) ) Extract, Sage extract, Celery extract, Soybean extract, Tachiko extract, Chimpi extract, Hikikoshi extract, Fukidanpopo extract, Button extract, Macombe extract, Melissa extract, Yuzu extract, Resvera Examples include various extracts derived from animals, plants and microorganisms such as trawl and lactic acid bacteria culture extract, and extracts obtained by fermenting vegetables, fruits and wild grasses (hereinafter referred to as wild grass fermented extracts). Examples of the raw material for fermenting wild grass include, for example, mugwort, dokudami, kitachialoe, turmeric, ginseng, wolfberry, pigeon, hypericum, umbilical cabbage, litchi, dandelion root, gypsophila, peach leaf, ginkgo biloba, edis gusano Seeds, Ninja, Fig leaf, Hubgrass, Safflower, Ezokogi, Achacharu, Lacanka, Eucommia leaf, Enmay grass, Loquat leaf, Morohaya, wolfberry leaf, Settsutsuboku, Akamegashiwa, Psyllium, Tulsi, Daylily, Pine leaf, Nanten leaf, Japanese cedar, Amadokoroko, Tsuyukusa, Megusuri tree, Tsuruna, Yam, Oyster leaf, Chamomile, Karin, Perilla leaf, Tangerine peel, Ginger, Mulberry leaf, Senshinren, Kumquat, Onion husk, Seven ginseng, Kyodo root, Jujube , Salacia, pepper, yew, red ginseng, Louis , Amla berries, boxweed, boxed bean, muirabuama, ibonashi tsuji rakuji, cat's claw, kombu, funori, mandarin, apple, pineapple, grape, fig, ume, melon, grapefruit, lemon, apricot, carrot, onion, parsley, burdock , Garlic, rakkyo, cabbage, shiitake and the like can be appropriately selected and used according to the application.
また、他のAGEs産生抑制剤としては、例えば、アマ、アマドコロ、オリーブ、カンアオイ、シナノキ、シモツケソウセンブリ、ニワトコ、バラ、ヒマワリ、ムラサキセンブリ、ユキノシタ、ワレモコウ等の植物抽出物などが例示できる。 Further, examples of other AGEs production inhibitors include plant extracts such as flax, amadokoroko, olives, kanaoi, lindens, citrus radish, elderberry, roses, sunflowers, purple flowers, cypresses, and walnuts.
経口の形態、飲食等としては、例えば、カプセル剤、錠剤、顆粒剤、粉剤、シロップ剤、液剤などの公知の形態に製剤化して自由に使用できる。飲食品の具体例として、例えば、ドリンク、サプリメントなどの栄養補助食品、特定保健用食品、機能性食品、健康食品などのほか、清涼飲料、スープ、クッキー、キャンディー、グミ、ガム等の各種一般加工食品が挙げられる。その際の賦形剤についても内服上許容しうる任意の液状及び固形状の原料を幅広く使用できるが、抗糖化という効果の面を考慮し、甘味料の選択に注意が必要である。すなわち、糖化しにくいものを選択すべきであり、例えば、ソルビトール、マルチトール、エリスリトール、ラクチトール、キシリトール、トレハロースおよびステビア等の糖アルコール、羅漢果抽出物、合成甘味料のアスパルテーム等を用いることが好ましい。 As oral forms, food and drink, etc., for example, it can be formulated into known forms such as capsules, tablets, granules, powders, syrups, liquids and the like and used freely. Specific examples of foods and drinks include, for example, nutritional supplements such as drinks and supplements, foods for specified health use, functional foods, health foods, and various general processing of soft drinks, soups, cookies, candy, gummies, gums, etc. Food. As the excipient at that time, any liquid and solid raw materials that are acceptable for internal use can be widely used. However, in consideration of the effect of anti-glycation, caution is required in selecting a sweetener. That is, those that are difficult to saccharify should be selected. For example, sugar alcohols such as sorbitol, maltitol, erythritol, lactitol, xylitol, trehalose and stevia, rahan fruit extract, aspartame of synthetic sweetener, and the like are preferably used.
飲食等の非経口でのサプリメントとしては、本発明の効果を損なわない範囲で、公知の滋養強壮剤や血行促進剤の適宜併用は任意である。 As a parenteral supplement such as food and drink, a known nutritional tonic or blood circulation promoter may be used in combination as long as the effects of the present invention are not impaired.
例えば、滋養強壮剤としては、すっぽんエキス、マムシエキス、ゴオウチンキ、ロクジョウ流エキス、エゾウコギエキス、杜仲エキス、カシュウエキスなどが例示できる。 For example, as a nourishing tonic, there can be exemplified a suppon extract, a beetle extract, a cinnamon tincture, a loachfish extract, an Ezocogi extract, a Tochu extract, a kashu extract and the like.
また、血行促進剤としては、グルコシルヘスペリジン、シトルリン、ビタミンEニコチネート、ニコチン酸、ニコチン酸アミド、ニコチン酸ベンジル、ショウキョウチンキ、トウガラシチンキ、ローズマリー酸などが例示できる。 Examples of the blood circulation promoter include glucosyl hesperidin, citrulline, vitamin E nicotinate, nicotinic acid, nicotinic acid amide, benzyl nicotinate, ginger tincture, chili pepper tincture, and rosemary acid.
第2の発明は、先述の第1の発明を追試する過程でなし得た発明であって、ED改善用および毛髪・睫毛機能改善用としての最適な組成物を提供するものである。 The second invention is an invention that can be made in the process of pursuing the first invention described above, and provides an optimal composition for improving ED and improving hair / lash function.
すなわち、本発明によれば、コラーゲンおよび/又はコラーゲンペプチドを主成分とし、これにエラスチン、ヒアルロン酸およびコンドロイチン硫酸から選ばれる少なくとも1種で構成される組成物に、特定のAGEs産生抑制剤を添加してなることを特徴とするED改善用組成物が提供される。 That is, according to the present invention, a specific AGEs production inhibitor is added to a composition comprising at least one selected from elastin, hyaluronic acid and chondroitin sulfate based on collagen and / or collagen peptide. Thus, an ED improving composition is provided.
また、本発明によれば、コラーゲンおよび/又はコラーゲンペプチドを主成分とし、これにエラスチン、ヒアルロン酸およびコンドロイチン硫酸から選ばれる少なくとも1種で構成される組成物に、特定のAGEs産生抑制剤を添加してなることを特徴とする毛髪・睫毛用組成物が提供される。 Further, according to the present invention, a specific AGEs production inhibitor is added to a composition comprising at least one selected from elastin, hyaluronic acid, and chondroitin sulfate as a main component of collagen and / or collagen peptide. Thus, a composition for hair and eyelashes is provided.
ここで、当該ED改善用組成物および毛髪・睫毛用組成物に添加する特定のAGEs産生抑制剤は、先述のアシュワガンダ、イカリソウ、オタネニンジン、ガラナ、黒ウコン、トリビュラス、トンカットアリ、ニンニク、プエラリア、マカ、ムイラプアマ、モリンガ、メシマコブ及びローヤルゼリーから選ばれた1種以上であり、さらにはAGEs産生抑制効果賦活剤としてミレットを配合したものである。 Here, the specific AGEs production inhibitor added to the composition for improving ED and the composition for hair and eyelashes is Ashwagandha, Ikarisou, Panax ginseng, guarana, black turmeric, tribulus, tonkat ant, garlic, Pueraria, It is at least one selected from maca, muirapuama, moringa, mesimacob, and royal jelly, and further contains millet as an activator for AGEs production suppression effect.
コラーゲンは、特段の制約はないが、吸収性を考慮するとコラーゲンペプチド、特に「プロリン―ヒドロキシプロリン」および/または「ヒドロキシプロリン―グリシン」で構成されるオリゴペプチド(ペプチド数10未満)やアテロコラーゲン類が好ましい。 Collagen is not particularly restricted, but considering absorbability, collagen peptides, particularly oligopeptides composed of “proline-hydroxyproline” and / or “hydroxyproline-glycine” (less than 10 peptides) and atelocollagens preferable.
エラスチンは、豚、牛などの哺乳類やマグロやサケ等の魚類から単離したコラーゲンの繊維を支える役割を有する弾性繊維である。体内吸収性を考慮すると、好適には、エラスターゼ,ペプシン,プロナーゼ等の蛋白質分解酵素により酵素的に加水分解するか、酸により加水分解した平均分子量100,000前後のものが使用できる。さらに、可溶化のし易さから平均分子量が20,000前後のものが良い。 Elastin is an elastic fiber having a role to support collagen fibers isolated from mammals such as pigs and cattle and fish such as tuna and salmon. In consideration of absorbability in the body, it is preferable to use those having an average molecular weight of around 100,000, which are enzymatically hydrolyzed by proteolytic enzymes such as elastase, pepsin and pronase, or hydrolyzed by acid. Furthermore, those having an average molecular weight of about 20,000 are preferable because of easy solubilization.
ヒアルロン酸は、N−アセチルグルコサミンとグルクロン酸とがベータ1,4結合した高分子多糖であり、好適にはヒアルロン酸をヒアルロニダーゼ等の酵素で分解した低分子のもの(平均分子量100,000前後)が使用できる。 Hyaluronic acid is a high-molecular polysaccharide in which N-acetylglucosamine and glucuronic acid are bonded to each other in beta 1,4, and preferably has a low molecular weight obtained by degrading hyaluronic acid with an enzyme such as hyaluronidase (average molecular weight around 100,000). Can be used.
コンドロイチン硫酸は、コンドロイチン6−硫酸及びコンドロイチン4−硫酸等の単体又はこれらの混合物である。分子量は特に限定されないが、体内吸収性を考慮すると平均分子量50,000が好ましい。本発明では、コンドロイチン硫酸の塩も使用でき、塩の種類は特に限定されないが、ナトリウム塩またはカリウム塩が好ましい。 Chondroitin sulfate is a simple substance such as chondroitin 6-sulfate and chondroitin 4-sulfate, or a mixture thereof. The molecular weight is not particularly limited, but an average molecular weight of 50,000 is preferable in view of absorbability in the body. In the present invention, a chondroitin sulfate salt can also be used, and the type of the salt is not particularly limited, but a sodium salt or potassium salt is preferred.
コラーゲンおよびエラスチンをAGEs産生抑制剤と組合せる意義は、生体内に存在するタンパク質の糖化をAGEs産生抑制剤で押えつつ、絶対量を補充し、生体内タンパク質本来の機能性を維持するというデュアル効果を期待するものである。その結果、恒常性の維持(ホメオスタシス)が図られる。 The significance of combining collagen and elastin with an AGEs production inhibitor is the dual effect of maintaining the original functionality of the protein in the body while supplementing the absolute amount while suppressing glycation of the protein present in the body with the AGEs production inhibitor. Is what you expect. As a result, the maintenance of homeostasis (homeostasis) is achieved.
第2の発明における有効成分、つまり特定のAGEs産生抑制剤の適用は第1の発明と同様である。また、非経口または経口の形態も上記の第1発明と同様であるが、コラーゲン、エラスチン、ヒアルロン酸およびコンドロイチン硫酸は、適用部位や製剤形態に応じて任意に配合しうるが、通常、製剤全体の0.01〜20重量%、好ましくは0.3〜10重量%で十分である。
AGEs産生抑制剤は、これらの配合量に対し1:0.01〜1:20、好ましくは1:0.1〜1:10が好ましい。
The application of the active ingredient in the second invention, that is, the specific AGEs production inhibitor is the same as in the first invention. The parenteral or oral form is the same as that of the first invention. Collagen, elastin, hyaluronic acid and chondroitin sulfate can be optionally mixed depending on the application site and the form of preparation, but usually the whole preparation 0.01 to 20% by weight, preferably 0.3 to 10% by weight is sufficient.
The AGEs production inhibitor is preferably in the range of 1: 0.01 to 1:20, preferably 1: 0.1 to 1:10, based on the blended amount.
第3の発明としては、第2の発明に係る組成物の使用方法を提供するものである。 As 3rd invention, the usage method of the composition which concerns on 2nd invention is provided.
すなわち、本発明によれば、コラーゲンおよび/又はコラーゲンペプチドを主成分とし、これにエラスチン、ヒアルロン酸およびコンドロイチン硫酸から選ばれる少なくとも1種で構成される組成物において、AGEs産生抑制剤を添加し、EDを改善する方法もしくは同じく頭皮機能を改善し、脱毛および白髪を防止する方法が提供される。 That is, according to the present invention, in a composition comprising at least one selected from elastin, hyaluronic acid and chondroitin sulfate based on collagen and / or collagen peptide as a main component, an AGEs production inhibitor is added, A method of improving ED or also improving scalp function and preventing hair loss and gray hair is provided.
また、本発明によれば、コラーゲンおよび/又はコラーゲンペプチドを主成分とし、これにエラスチン、ヒアルロン酸およびコンドロイチン硫酸から選ばれる少なくとも1種で構成される組成物において、AGEs産生抑制剤を添加し、さらにAGEs産生抑制効果賦活剤としてミレットを添加したことを特徴とするEDを改善する方法もしくは同じく頭皮機能を改善し、脱毛および白髪を防止する方法が提供される。 Further, according to the present invention, in a composition comprising at least one selected from elastin, hyaluronic acid and chondroitin sulfate as a main component of collagen and / or collagen peptide, an AGEs production inhibitor is added, Furthermore, there is provided a method for improving ED characterized by adding millet as an AGEs production inhibitory effect activator or a method for improving scalp function and preventing hair loss and gray hair.
コラーゲン類を主成分として含む組成物に特定のAGEs産生抑制剤を組合せ、コラーゲン類等の生体内での絶対量を調整しつつ、糖化反応を抑制することでED改善や脱毛および白髪防止を図るという着想はこれまでになく、本発明組成物の使用方法はこれまでにない新規な発明である。 A composition containing collagens as a main component is combined with a specific AGEs production inhibitor, and the glycation reaction is suppressed while adjusting the absolute amount of collagen and the like in vivo, thereby improving ED and preventing hair loss and white hair. The idea of using the composition of the present invention is a novel invention that has never been seen before.
第3の発明では、第1および第2の発明で得たAGEs産生抑制剤またはその組成物は、飲食等の経口形態での服用は、毎日、好ましくは食間に行い、外用での場合は、最低1日1回を適量、患部に適用するのが良い。理想的には、経口で毎日服用して体内ケアを継続し、用時に外用でケアする。すなわち、経口でのケアを主とし、外用でのケアを副とするのが効果の点で好ましい。 In the third invention, the AGEs production inhibitor or composition thereof obtained in the first and second inventions is taken daily in an oral form such as food and drink, preferably between meals, and for external use, Appropriate amount at least once a day should be applied to the affected area. Ideally, take it daily orally and continue internal care, and take external care when using. That is, it is preferable in terms of effect that oral care is the main and external care is the secondary.
以上に説明したように、本発明によれば、生体内の糖化反応による弊害、特に加齢によって失われるコラーゲン、エラスチン等の生体内タンパク質の絶対量と機能性低下という課題を解決できるAGEs産生抑制剤またはその組成物ならびにこれらの使用方法が提供され、これによってED改善、脱毛・白髪の防止が図られる。 As described above, according to the present invention, AGEs production suppression that can solve the problems of in vivo saccharification reaction, in particular, the absolute amount of in vivo proteins such as collagen and elastin lost due to aging and functional decline. An agent or a composition thereof and a method of using these agents are provided, thereby improving ED and preventing hair loss and white hair.
以下、実施例(製造例並びに効果の試験例及び処方例)により本発明をさらに具体的に説明するが、本発明の範囲は当該実施例に限定されるものではない。
<製造例1>
乾燥させたアシュワガンダの葉100gに水5kgを加え、室温で24時間抽出しろ過し、アシュワガンダ抽出液を得た。
<製造例2>
乾燥させたイカリソウの全草500gに水5kgを加え、40℃で3時間加熱抽出しろ過してイカリソウ抽出液を得た。
<製造例3>
オタネニンジンの根を細切し、乾燥させたもの200gを水5kgで煎じてろ過し、オタネニンジン抽出液を得た。
<製造例4>
ガラナの種子500gを砕き、水1kg、エタノール4kgを加えて、40℃で5時間加熱抽出し、ろ過してガラナ抽出液を得た。
<製造例5>
黒ウコン200gを細切し、水5kgを加えて煎じる。その後ろ過し、黒ウコン抽出液を得た。
<製造例6>
トリビュラスの葉300gに水3kg、エタノール2kgを加え、室温で5時間抽出し、ろ過してトリビュラス抽出液を得た。
<製造例7>
トンカットアリの根を粉末にし、200gを水5kgで煎じる。ろ過してトンカットアリ抽出液を得た。
<製造例8>
ニンニク50gをスライスし、水5kgを加えた後、室温で24時間抽出し、ろ過してニンニク抽出液を得た。
<製造例9>
プエラリア100gを細切し、水1kg、アルコール4kgを加えて40度で6時間抽出し、ろ過してプエラリア抽出液を得た。
<製造例10>
乾燥したマカの根100gを粉末にし、熱水5kgで抽出後、ろ過してマカ抽出液を得た。
<製造例11>
ムイラプアマの樹皮300gを粉末にし、水3kg、エタノール2kgを加えて60度で5時間抽出後、ろ過してムラプアマ抽出液を得た。
<製造例12>
モリンガの葉500gを水5kgを加えて6時間煎じる。ろ過後、モリンガ抽出液を得た。
<製造例13>
メシマコブの子実体300gを細切し、水500g、エタノール4.5kgを加えて40度で24時間抽出し、ろ過してメシマコブ抽出液を得た。
<製造例14>
生ローヤルゼリー500gにエタノール5kgを加え、室温で10時間抽出後、ろ過してローヤルゼリー抽出液を得た。
<製造例15>
乾燥したキビ100gを粉末にし、水5kgを加え、50度で24時間抽出後、ろ過してキビ抽出液を得た。
Hereinafter, the present invention will be described more specifically by way of examples (manufacturing examples and test examples and formulation examples of effects), but the scope of the present invention is not limited to these examples.
<Production Example 1>
5 kg of water was added to 100 g of dried Ashwagandha leaves, extracted at room temperature for 24 hours and filtered to obtain an Ashwagandha extract.
<Production Example 2>
Water (5 kg) was added to 500 g of dried icarius plant, heated and extracted at 40 ° C. for 3 hours, and filtered to obtain a licorice extract.
<Production Example 3>
200 g of dried ginseng root was decocted with 5 kg of water and filtered to obtain a ginseng extract.
<Production Example 4>
500 g of guarana seeds were crushed, 1 kg of water and 4 kg of ethanol were added, extracted by heating at 40 ° C. for 5 hours, and filtered to obtain a guarana extract.
<Production Example 5>
Chop 200 g of black turmeric, add 5 kg of water, and roast. Thereafter, filtration was performed to obtain a black turmeric extract.
<Production Example 6>
3 kg of water and 2 kg of ethanol were added to 300 g of Tribulus leaves, extracted at room temperature for 5 hours, and filtered to obtain a Tribulus extract.
<Production Example 7>
Tonkat ant root is powdered and 200 g is decocted with 5 kg of water. Filtration was performed to obtain a tonkat ant extract.
<Production Example 8>
After slicing 50 g of garlic and adding 5 kg of water, it was extracted at room temperature for 24 hours and filtered to obtain a garlic extract.
<Production Example 9>
100 g of Pueraria was chopped, 1 kg of water and 4 kg of alcohol were added, extracted at 40 ° C. for 6 hours, and filtered to obtain a Pueraria extract.
<Production Example 10>
100 g of dried maca root was powdered, extracted with 5 kg of hot water, and then filtered to obtain a maca extract.
<Production Example 11>
300 g of muirapuama bark was made into powder, 3 kg of water and 2 kg of ethanol were added and extracted at 60 ° C. for 5 hours, followed by filtration to obtain a Murapuama extract.
<Production Example 12>
Add 5 kg of water to 500 g of Moringa leaves and decoct for 6 hours. After filtration, a Moringa extract was obtained.
<Production Example 13>
300 g of fruit body of Meshimakobu was chopped, 500 g of water and 4.5 kg of ethanol were added, extracted at 40 degrees for 24 hours, and filtered to obtain Meshimakobu extract.
<Production Example 14>
5 kg of ethanol was added to 500 g of raw royal jelly, extracted at room temperature for 10 hours, and then filtered to obtain a royal jelly extract.
<Production Example 15>
100 g of dried millet was powdered, 5 kg of water was added, extracted at 50 degrees for 24 hours, and then filtered to obtain a millet extract.
<試験例1>AGEs産生抑制剤試験
(試験方法)
試験全般は、Yokozawaらの方法(Yokozawa,T.;Nakagawa,T.;Journal of Traditional Medicines.18,107−112(2001))に準拠して実施した。
(1)反応液の調製
100mMのリン酸緩衝液(pH7.4)にD-グルコース、 D−(−)−フルクトースおよびBSA(牛血清アルブミン)を加えて溶解し、それぞれ25mM、25mM、10mg/mLになるように反応液を調製した。
(2)試料の調製
試料(製造例1乃至15の各抽出液)およびコントロールは精製水を試験に供した。また、比較対照(ポジィティヴコントロール)にはアミノグアニジンを用い、精製水で最終濃度が0.2mMとなるように調製した。
(3)試験実施要領
各濃度に調製した試料およびコントロールをそれぞれ試験管に添加し、コントロールにはリン酸緩衝液を、コントロール以外には反応液を添加後、密閉混合した。これら試験溶液を60℃で18時間インキュベートした。インキュベート後は試験管を氷冷し、さらに室温に戻したものを、分光蛍光光度計で蛍光強度を測定した(波長;励起360nm・蛍光450nm)。AGEs産生抑制率は、次式により求めた。
AGEs産生抑制率(%)=
[1−(試料の蛍光強度−試料ブランクの蛍光強度/コントロールの蛍光強度
−コントロールブランクの蛍光強度)] ×100
<Test Example 1> AGEs production inhibitor test (test method)
The entire test was performed according to the method of Yokozawa et al. (Yokozawa, T .; Nakagawa, T .; Journal of Traditional Medicines. 18, 107-112 (2001)).
(1) Preparation of reaction solution D-glucose, D-(-)-fructose and BSA (bovine serum albumin) were added to 100 mM phosphate buffer (pH 7.4) and dissolved, and 25 mM, 25 mM, 10 mg / kg, respectively. The reaction solution was prepared to be mL.
(2) Preparation of sample The sample (each extract of Production Examples 1 to 15) and the control used purified water for the test. In addition, aminoguanidine was used as a comparative control (positive control) and prepared with purified water to a final concentration of 0.2 mM.
(3) Test procedure The sample and control prepared to each concentration were added to each test tube, a phosphate buffer solution was added to the control, and a reaction solution was added to other than the control, followed by airtight mixing. These test solutions were incubated at 60 ° C. for 18 hours. After the incubation, the test tube was cooled on ice and returned to room temperature, and the fluorescence intensity was measured with a spectrofluorometer (wavelength; excitation 360 nm, fluorescence 450 nm). The AGEs production inhibition rate was determined by the following equation.
AGE production inhibition rate (%) =
[1- (Sample fluorescence intensity−Sample blank fluorescence intensity / Control fluorescence intensity
-Fluorescence intensity of control blank)] × 100
(結果と考察)
結果を表1に示す。この結果から明らかなように、本発明の抽出液は、いずれも高いAGEs産生抑制作用を有することが明らかであり、これらを外用及び/又は経口の形態で最適に適用することで、皮膚組織におけるコラーゲンおよびエラスチン量の減少が防止でき、本願発明の目的とする機能改善・正常化が図られる。
The results are shown in Table 1. As is clear from this result, it is clear that all of the extracts of the present invention have a high AGEs production inhibitory effect, and by applying these optimally in an external and / or oral form, Reduction of the amount of collagen and elastin can be prevented, and the functional improvement and normalization targeted by the present invention can be achieved.
<試験例2>使用試験
(試験方法)
年齢50代の男性パネラーによる使用試験を行った。
評価パネラーは、発明品(有効成分を配合したドリンク剤)を適用する群およびプラセボ(有効成分を除く他の基剤は同じドリンク剤)を適用する群に分けた。そして、それぞれのパネラーについて、6カ月間使用後に、使用前と比較した本発明組成物の改善効果を、以下の評価項目により確認した。
評価1 毛髪改善効果 その1 毛髪のハリ・コシ感・抜け毛の程度
1.大いに改善 2.改善 3.やや改善 4.不変 5.悪化
評価2 毛髪改善効果 その2 毛髪の白髪の発生防止
1.大いに改善 2.改善 3.やや改善 4.不変 5.悪化
評価3 睫毛改善効果 睫毛の弾力性・ハリ・ツヤの程度
1.大いに改善 2.改善 3.やや改善 4.不変 5.悪化
評価4 男性機能改善効果 勃起能・性機能(持続性)
1.大いに改善 2.改善 3.やや改善 4.不変 5.悪化
(供試試料)
1.有効成分a群
コラーゲンペプチド15,000mg、エラスチン300mg、ヒアルロン酸ナトリウム130mgおよびコンドロイチン硫酸ナトリウム130mgに精製水100mLを加えて撹拌混合する。
2.有効成分b群
AGEs産生抑制剤として、製造例1乃至15のエキス(乾固物)をそれぞれ100mgに精製水100mLを加えて撹拌混合する。
3.試料調製
1に2を加えて撹拌混合し、甘味料としてトレハロースおよびステビアを適量加えたものを調製後、これに微量の着香料を加えて試料に供した。
<Test Example 2> Use test (test method)
A use test was conducted by a male panelist at the age of 50.
The evaluation panel was divided into a group to which the invention product (drink preparation containing the active ingredient) was applied and a placebo (the other base other than the active ingredient was the same drink preparation). And about each paneler, the improvement effect of this invention composition compared with before use after 6 months use was confirmed with the following evaluation items.
Evaluation 1 Hair improvement effect 1 Degree of hair firmness, firmness and hair loss Great improvement Improvement Slightly improved 4. Invariant 5. Deterioration evaluation 2 Hair improvement effect 2 Prevention of occurrence of white hair in hair 1. Great improvement Improvement Slightly improved Invariant 5. Deterioration evaluation 3 Eyelash improvement effect The degree of elasticity, firmness and gloss of eyelashes Great improvement Improvement Slightly improved Invariant 5. Deterioration assessment 4 Male function improvement effect Erection / sexual function (sustainability)
1. Great improvement Improvement Slightly improved Invariant 5. Deterioration (test sample)
1. Active ingredient a group 100 mL of purified water is added to 15,000 mg of collagen peptide, 300 mg of elastin, 130 mg of sodium hyaluronate and 130 mg of chondroitin sulfate, and mixed with stirring.
2. As an active ingredient b group AGEs production inhibitor, 100 mL of purified water is added to 100 mg of the extract (dried product) of Production Examples 1 to 15 and stirred and mixed.
3. Sample preparation 1 was added to 2 and mixed by stirring. After preparing a proper amount of trehalose and stevia as sweeteners, a small amount of flavoring was added to the sample and used as a sample.
(結果と考察)
結果を表2に示す。この結果から明らかなように、本発明の組成物には、優れた毛髪改善効果、睫毛改善効果及び男性性機能改善効果が認められた。当該男性性機能改善の効果に鑑みれば、本発明の組成物は、男性不妊症治療にも有効であることが十分に期待できる。
The results are shown in Table 2. As is apparent from this result, the composition of the present invention was found to have excellent hair improving effect, eyelash improving effect and male sexual function improving effect. In view of the effect of improving the male sexual function, the composition of the present invention can be sufficiently expected to be effective in treating male infertility.
以下に、本発明の処方例を挙げるが、本発明の範囲は下記の処方例に限定されるものではない。 Although the formulation example of this invention is given to the following, the scope of the present invention is not limited to the following formulation example.
ドリンク剤の処方例を表3に示した。これら5つの処方はいずれも、試験例2で示した結果同様に、本発明の目的とする効果を有していた。
ローション剤の処方例を表4に示した。これら5つの処方はいずれも、試験例2で示した結果同様に、本発明の目的とする効果を有していた。
育毛剤の処方例を表5に示した。これら5つの処方はいずれも、試験例2で示した結果同様に、本発明の目的とする効果を有していた。
シャンプーの処方例を表6に示した。これら5つの処方はいずれも、試験例2で示した結果同様に、本発明の目的とする毛髪適用上の効果を有していた。
コンディショナーの処方例を表7に示した。これら5つの処方はいずれも、試験例2で示した結果同様に、本発明の目的とする毛髪適用上の効果を有していた。
Table 7 shows an example of the conditioner formulation. As with the results shown in Test Example 2, all of these five formulations had the effect on hair application that is the object of the present invention.
Claims (14)
12. The method for preventing hair loss and white hair by improving the scalp according to claim 10, wherein the application is a parenteral external form.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014223844 | 2014-11-01 | ||
JP2014223844 | 2014-11-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2016088933A true JP2016088933A (en) | 2016-05-23 |
Family
ID=56017566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015213529A Pending JP2016088933A (en) | 2014-11-01 | 2015-10-29 | Age production inhibitor and application thereof |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2016088933A (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016160198A (en) * | 2015-02-27 | 2016-09-05 | 株式会社東洋新薬 | Black ginger-containing composition |
JP2017132747A (en) * | 2016-01-30 | 2017-08-03 | 育宏 南 | Age production inhibitor |
JP2017210452A (en) * | 2016-05-27 | 2017-11-30 | 株式会社レーネ | Protein glycation reaction inhibitor |
JP2018002655A (en) * | 2016-07-01 | 2018-01-11 | 小林製薬株式会社 | Formulation containing pelodiscus sinensis and panax ginseng |
JP2018011569A (en) * | 2016-07-22 | 2018-01-25 | 日華化学株式会社 | Food composition for hair scalp state improvement |
CN108078905A (en) * | 2018-02-08 | 2018-05-29 | 陕西莹润生物医药科技有限公司 | Anticreep shampoo for men only and its processing method |
JP2018111671A (en) * | 2017-01-13 | 2018-07-19 | 小林製薬株式会社 | Oral composition |
CN111418748A (en) * | 2020-05-22 | 2020-07-17 | 武汉华嫩科技有限公司 | Elastic and collagen double-protein peptide beverage and preparation method thereof |
WO2020230011A1 (en) * | 2019-05-13 | 2020-11-19 | Guglielmo Buonamici | Human nutraceutical supplement |
JP2020193230A (en) * | 2020-09-02 | 2020-12-03 | 株式会社東洋新薬 | Kaempferia parviflora-containing compositions |
JP2020536590A (en) * | 2017-10-13 | 2020-12-17 | クリスタルファルマ・ソチエタ・ア・レスポンサビリタ・リミタータ | Supplements to relieve women's disabilities caused by aging |
WO2021015040A1 (en) * | 2019-07-25 | 2021-01-28 | 新田ゼラチン株式会社 | Hair growing agent and food and drink containing same |
JP2021035350A (en) * | 2019-08-21 | 2021-03-04 | 国安 王 | Food product for stimulating bone strengthening, periosteal repair, fracture healing and hair blackening |
CN113349233A (en) * | 2021-06-19 | 2021-09-07 | 武汉轻工大学 | Nutrition-enriched cookie and preparation method thereof |
EP4201418A1 (en) * | 2021-12-23 | 2023-06-28 | ASC Regenity Ltd. | Hair care nutritional supplement composition |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58162511A (en) * | 1982-03-23 | 1983-09-27 | Sakahito Matsuno | Hair nourishing composition |
JPH1081615A (en) * | 1996-08-16 | 1998-03-31 | Kao Corp | Composition for treating hair and scalp |
JP2004250445A (en) * | 2003-01-31 | 2004-09-09 | Yakult Honsha Co Ltd | Glycation inhibitor and its use |
JP2007022923A (en) * | 2005-07-12 | 2007-02-01 | Lion Corp | Hair follicle apoptosis reaction inhibitor and hair cosmetic composition |
JP2008063254A (en) * | 2006-09-05 | 2008-03-21 | Oriza Yuka Kk | Composition for enhancing reproductive function |
WO2009110546A1 (en) * | 2008-03-06 | 2009-09-11 | 独立行政法人産業技術総合研究所 | Composition containing aqueous extract of ashwaganda leaves as the active ingredient and method of producing the same |
JP2011190217A (en) * | 2010-03-15 | 2011-09-29 | Combi Corp | Human epidermal cell growth promoter, and skin care composition for external use and cosmetic each containing the same |
JP2012140437A (en) * | 2004-04-27 | 2012-07-26 | Ramaswamy Rajendran | Use of pregnane glycoside in treatment/management of obesity, obesity-related disorder, and other disorder |
JP2012229170A (en) * | 2011-04-25 | 2012-11-22 | Oriza Yuka Kk | Nitrogen monoxide production inhibitor |
JP2014500275A (en) * | 2010-12-06 | 2014-01-09 | フォリカ,インコーポレイテッド | Methods for treating baldness and for promoting hair growth |
WO2014017145A1 (en) * | 2012-07-24 | 2014-01-30 | 株式会社J-オイルミルズ | Composition |
JP2014118366A (en) * | 2012-12-13 | 2014-06-30 | Pola Chem Ind Inc | Advanced glycation end product decomposer |
-
2015
- 2015-10-29 JP JP2015213529A patent/JP2016088933A/en active Pending
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58162511A (en) * | 1982-03-23 | 1983-09-27 | Sakahito Matsuno | Hair nourishing composition |
JPH1081615A (en) * | 1996-08-16 | 1998-03-31 | Kao Corp | Composition for treating hair and scalp |
JP2004250445A (en) * | 2003-01-31 | 2004-09-09 | Yakult Honsha Co Ltd | Glycation inhibitor and its use |
JP2012140437A (en) * | 2004-04-27 | 2012-07-26 | Ramaswamy Rajendran | Use of pregnane glycoside in treatment/management of obesity, obesity-related disorder, and other disorder |
JP2007022923A (en) * | 2005-07-12 | 2007-02-01 | Lion Corp | Hair follicle apoptosis reaction inhibitor and hair cosmetic composition |
JP2008063254A (en) * | 2006-09-05 | 2008-03-21 | Oriza Yuka Kk | Composition for enhancing reproductive function |
WO2009110546A1 (en) * | 2008-03-06 | 2009-09-11 | 独立行政法人産業技術総合研究所 | Composition containing aqueous extract of ashwaganda leaves as the active ingredient and method of producing the same |
JP2011190217A (en) * | 2010-03-15 | 2011-09-29 | Combi Corp | Human epidermal cell growth promoter, and skin care composition for external use and cosmetic each containing the same |
JP2014500275A (en) * | 2010-12-06 | 2014-01-09 | フォリカ,インコーポレイテッド | Methods for treating baldness and for promoting hair growth |
JP2012229170A (en) * | 2011-04-25 | 2012-11-22 | Oriza Yuka Kk | Nitrogen monoxide production inhibitor |
WO2014017145A1 (en) * | 2012-07-24 | 2014-01-30 | 株式会社J-オイルミルズ | Composition |
JP2014118366A (en) * | 2012-12-13 | 2014-06-30 | Pola Chem Ind Inc | Advanced glycation end product decomposer |
Non-Patent Citations (4)
Title |
---|
ASIAN JOURNAL OF ANDROLOGY, vol. 4, JPN6018034441, 2002, pages 295 - 298, ISSN: 0003934664 * |
INTERNATIONAL FOOD RESEARCH JOURNAL, vol. 18, no. 3, JPN6018034438, 2011, pages 915 - 923, ISSN: 0003934661 * |
JOURNAL OF ETHNOPHARMACOLOGY, vol. 74, JPN6018034439, 2001, pages 1 - 6, ISSN: 0003934662 * |
VASCULAR PHARMACOLOGY, vol. 44, JPN6018034440, 2006, pages 406 - 410, ISSN: 0003934663 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016160198A (en) * | 2015-02-27 | 2016-09-05 | 株式会社東洋新薬 | Black ginger-containing composition |
JP2017132747A (en) * | 2016-01-30 | 2017-08-03 | 育宏 南 | Age production inhibitor |
JP2017210452A (en) * | 2016-05-27 | 2017-11-30 | 株式会社レーネ | Protein glycation reaction inhibitor |
JP2018002655A (en) * | 2016-07-01 | 2018-01-11 | 小林製薬株式会社 | Formulation containing pelodiscus sinensis and panax ginseng |
JP2018011569A (en) * | 2016-07-22 | 2018-01-25 | 日華化学株式会社 | Food composition for hair scalp state improvement |
JP2018111671A (en) * | 2017-01-13 | 2018-07-19 | 小林製薬株式会社 | Oral composition |
JP2020536590A (en) * | 2017-10-13 | 2020-12-17 | クリスタルファルマ・ソチエタ・ア・レスポンサビリタ・リミタータ | Supplements to relieve women's disabilities caused by aging |
CN108078905A (en) * | 2018-02-08 | 2018-05-29 | 陕西莹润生物医药科技有限公司 | Anticreep shampoo for men only and its processing method |
WO2020230011A1 (en) * | 2019-05-13 | 2020-11-19 | Guglielmo Buonamici | Human nutraceutical supplement |
WO2021015040A1 (en) * | 2019-07-25 | 2021-01-28 | 新田ゼラチン株式会社 | Hair growing agent and food and drink containing same |
US20220305090A1 (en) * | 2019-07-25 | 2022-09-29 | Nitta Gelatin Inc. | Hair growing agent and food or beverage product comprising same |
JP2021035350A (en) * | 2019-08-21 | 2021-03-04 | 国安 王 | Food product for stimulating bone strengthening, periosteal repair, fracture healing and hair blackening |
CN111418748A (en) * | 2020-05-22 | 2020-07-17 | 武汉华嫩科技有限公司 | Elastic and collagen double-protein peptide beverage and preparation method thereof |
JP2020193230A (en) * | 2020-09-02 | 2020-12-03 | 株式会社東洋新薬 | Kaempferia parviflora-containing compositions |
CN113349233A (en) * | 2021-06-19 | 2021-09-07 | 武汉轻工大学 | Nutrition-enriched cookie and preparation method thereof |
CN113349233B (en) * | 2021-06-19 | 2023-04-25 | 武汉轻工大学 | Nutrient enrichment cookie and preparation method thereof |
EP4201418A1 (en) * | 2021-12-23 | 2023-06-28 | ASC Regenity Ltd. | Hair care nutritional supplement composition |
WO2023118518A1 (en) * | 2021-12-23 | 2023-06-29 | ASC REGENITY Limited | Hair care nutritional supplement composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016088933A (en) | Age production inhibitor and application thereof | |
US5925348A (en) | Methods utilizing compositions containing sacred lotus (methyltransferase) to treat aging skin | |
JP3966922B2 (en) | Fibroblast growth promoter | |
CN102647920B (en) | Acacia macrostachya seed extract and compositions containing same | |
JP4205188B2 (en) | Maillard reaction inhibitor | |
US20020098253A1 (en) | Oral compositions containing lotus | |
WO2007037060A1 (en) | Composition for acceleration of type i collagen production | |
JP2002138045A (en) | Inhibitor for inhibiting differentiation induction of pre- adipocyte | |
KR102432924B1 (en) | Extract and composition comprising plant-derived collagen and mucin | |
CN103282041A (en) | Extract of aerial parts of maca rich in polyphenols and composition comprising same | |
JP2003095913A (en) | Cosmetic composition or food and drink | |
JPH1053532A (en) | Antiallergic drug containing plant extract | |
KR101744103B1 (en) | Composition for preventing hair loss and promoting hair growth and mathod for preparing the same | |
JP2007099650A (en) | Abnormal protein removal composition | |
JP7213307B2 (en) | Composition for activating protein L-isoaspartate methyltransferase | |
JP2002238497A (en) | Food composition | |
CN105407866A (en) | Combination of active agents for treating skin aging | |
WO2021005941A1 (en) | Albizia julibrissin extract-containing composition | |
KR20130088997A (en) | Cosmetic composition for hair growth and restoration from caviar extracts and its fermentation | |
KR101757469B1 (en) | Compositions for promoting hair growth and inhibiting inflammation comprising mixed extracts of natural products | |
KR101547758B1 (en) | Composition for preventing hair loss and promoting hair growth | |
JP2017132747A (en) | Age production inhibitor | |
KR20230174204A (en) | Cosmetic composition comprising nanking cherry extract and soluble collagen | |
JP6861134B2 (en) | Hyaluronic acid production promoter and hyaluronic acid production promoter food | |
JP2001233727A (en) | Cosmetic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171029 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180911 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181111 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20181211 |